Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 68

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 68
---
 Connect Biopharma Holdings Limited as of December 31, 2024 and 2023 and for the
years then ended, which are incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2024, have been so incorporated in reliance on the report of CBIZ
CPAs P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

55

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission, of which this prospectus is a part, is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED JUNE 10, 2025

PROSPECTUS

Up to $150,000,000 of American Depositary Shares

Representing Ordinary Shares

Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited, a holding company incorporated in the Cayman Islands in November 2015
(“Connect,” the “Company,” the “Group,” “we,” “us,” “our,” “our company” and “Connect Biopharma”) is party to a sales agreement (the “Sales Agreement”), with
and Cantor Fitzgerald & Co. (“Cantor”), dated April 15, 2022, as amended on June 10, 2025, relating to the American Depositary Shares (“ADSs”) offered by this prospectus. Each ADS represents one of our ordinary
shares, par value $0.000174 per share (“Ordinary Shares”). Under this prospectus, we may offer and sell ADSs having an aggregate offering price of up to $150.0 million from time to time through Cantor (the “Sales Agent”),
acting as our agent, in accordance with the Sales Agreement. As of June 10, 2025, we have not sold any ADSs under the Sales Agreement.

Sales of the ADSs, if any, under this prospectus may be made by any method permitted that is deemed an “at the
market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on or through the Nasdaq Global